|
Video: What is a Stock Split?
|
|
Qualigen Therapeutics is a life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. Co.'s drug compound QN-302 is being developed to target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways for treatment of G4-targeted tumors. The investigational compounds within Co.'s RAS portfolio are designed to suppress the interaction of endogenous RAS with c-RAF, upstream of the KRAS, HRAS and NRAS effector pathways. Co.'s anticancer drug candidate, QN-247 is aptamer-based to treat a variety of cancer types, including liquid and solid tumors. According to our QLGN split history records, Qualigen Therapeutics has had 2 splits. | |
|
Qualigen Therapeutics (QLGN) has 2 splits in our QLGN split history database. The first split for QLGN took place on May 26, 2020. This was a 1 for 25 reverse split, meaning for each 25 shares of QLGN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 40 share position following the split. QLGN's second split took place on November 23, 2022. This was a 1 for 10 reverse split, meaning for each 10 shares of QLGN owned pre-split, the shareholder now owned 1 share. For example, a 40 share position pre-split, became a 4 share position following the split.
When a company such as Qualigen Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the QLGN split history from start to finish, an original position size of 1000 shares would have turned into 4 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Qualigen Therapeutics shares, starting with a $10,000 purchase of QLGN, presented on a split-history-adjusted basis factoring in the complete QLGN split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/24/2015 |
|
End date: |
04/23/2024 |
|
Start price/share: |
$1,240.00 |
|
End price/share: |
$0.32 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.97% |
|
Average Annual Total Return: |
-60.80% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$2.54 |
|
Years: |
8.84 |
|
|
|
Date |
Ratio |
05/26/2020 | 1 for 25 | 11/23/2022 | 1 for 10 |
|
|